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Summary
Objectives Traumatic brain injury (TBI) is a major cause of
long-term disability with variable recovery. Preclinical studies
suggest that vitamin D status influences the recovery after TBI.
However, there is no published clinical data on links between
vitamin D status and TBI outcomes. The aim was to determine
the (i) prevalence of vitamin D deficiency/insufficiency, and
associations of vitamin D status with (ii) demographic factors
and TBI severity, and with (iii) cognitive function, symptoms
and quality of life, in adults after TBI.
Design Retrospective audit of patients seen between July 2009
and March 2015. Serum vitamin D (25-hydroxy-cholecalciferol)
was categorized as deficient (<40 nmol/l), insufficient (40–
70 nmol/l) or replete (>70 nmol/l).
Patients A total of 353 adults seen in tertiary hospital clinic
(754% lighter skinned, 748% male, age median 351 year, range
266–483 year), 03–565 months after TBI (745% moderate–
severe).
Measurements Serum vitamin D concentrations; Adden-
brooke’s Cognitive Examination (ACE-R), Beck Depression
Inventory-II (BDI-II), SF-36 Quality of Life, Pittsburgh Sleep
Quality Index.
Results In total, 465% of patients after TBI had vitamin D
deficiency and 802% insufficiency/deficiency. Patients with
vitamin D deficiency had lower ACE-R scores than those of
vitamin D replete (mean effect size  SEM 45  21,
P = 0034), and higher BDI-II scores than those of vitamin D
insufficient (45  16, P = 0003), correcting for age, gender,
time since TBI and TBI severity. There was no association
between vitamin D status and markers of TBI severity, sleep
or quality of life.
Conclusion Vitamin D deficiency is common in patients after
TBI and associated with impaired cognitive function and more
severe depressive symptoms.
(Received 27 January 2016; returned for revision 6 February 2016;
finally revised 17 February 2016; accepted 22 February 2016)
Introduction
Each year, 14 million people attend emergency departments in
England and Wales with a recent traumatic brain injury (TBI).1
TBI is a major cause of long-term disability often leading to
neuropsychiatric and cognitive impairments, including problems
with memory and executive function, mood, sleep disturbance
and lethargy. Recovery after TBI varies markedly between
patients. Neuroendocrine dysfunction leading to pituitary hor-
mone deficiencies after TBI may contribute to persistent symp-
toms, especially growth hormone deficiency, with 5–20% of TBI
patients reported as having hypothalamic–pituitary dysfunction.2
Vitamin D is another hormonal factor that could influence
recovery after TBI. Vitamin D is a fat-soluble sercosteroid essen-
tial for musculoskeletal health that is primarily synthesized in
the skin upon sun exposure. The prevalence of vitamin D defi-
ciency may be increased after TBI because of reduced sun expo-
sure as a result of hospitalization, impaired social functioning
and absence from work, resulting in more time spent indoors.
Vitamin D deficiency has been associated with many systemic
conditions, such as obesity, cardiovascular and neurodegenerative
diseases.3,4 Several meta-analyses have linked vitamin D status to
depression 5,6 (Table S2) and impaired cognitive function.7–10
However, these clinical findings are from association studies and
so it is difficult to infer causation as any disorder that decreases
exposure to sunlight, such as depression, may cause vitamin D
deficiency. Nevertheless, meta-analyses of intervention studies
have demonstrated improvements in depressive symptoms with
vitamin D supplementation, especially if subjects are vitamin D
deficient or clinically depressed at baseline (Table S3), which
would motivate vitamin D replacement in clinical practice.
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Depression and cognitive impairment are also common conse-
quences after TBI, with the prevalence of depression ranging
from 6 to 77%, and cognitive problems with memory, attention
and executive functioning are frequently seen.9,10 Vitamin D sta-
tus may therefore play a role in the development or exacerbation
of cognitive and psychiatric problems after TBI, impacting
recovery and quality of life. Vitamin D receptors and the vita-
min D-activating enzyme, 1-alpha-hydroxylase, are widely dis-
tributed in the human brain.11 Importantly, animal studies show
that vitamin D status can influence behavioural recovery, includ-
ing memory, and neuropathology after TBI.4,12 Neuroinflamma-
tion is a common consequence of TBI that may impair
recovery,13 and may be a linking mechanism for the beneficial
effects of vitamin D in rat models of TBI.4,12,14
Vitamin D status is best assessed using serum 25-hydroxy-
cholecalciferol, 25(OH)D3, concentration, as this is the major
circulating form of vitamin D with a long half-life of
2–3 weeks.15 United Kingdom national surveys suggest that
approximately 20% of adults can have low vitamin D status,16
with seasonal variation meaning that in winter this can reach
50% of White adults.17 Levels are also lower in subjects with
darker skin as melanin absorbs UV-B radiation from sunlight.18
Vitamin D status can be classified as replete, insufficient or defi-
cient, using established criteria (Table S1).
However, there are no published clinical data on the preva-
lence of vitamin D deficiency in patients after TBI or its associa-
tion with poorer clinical outcomes. Therefore, the purpose of
this retrospective cohort study was to determine the prevalence
of vitamin D deficiency and insufficiency after TBI, and whether
it is associated with severity of TBI, greater cognitive impair-
ment, worse symptoms and quality of life.
Methods
Study design
Case records were retrospectively reviewed from 581 new
patients attending the multidisciplinary adult TBI clinic at Char-
ing Cross/St Mary’s Hospitals, Imperial College Healthcare NHS
Trust (ICHNT), London, UK, between July 2009 and March
2015, to collate data from their first outpatient appointment
when vitamin D status was assessed. All data were collected
as part of routine clinical care. Patients taking part in neu-
roimaging research also gave written consent to allow records to
be accessed (Research Ethics Committee West London 09/
H0707/82).
Inclusion/exclusion criteria
Inclusion criteria were as follows: (i) either gender, (ii) any age,
(iii) experienced at least one TBI of any severity19 and (iv) any
ethnicity. Exclusion criteria were as follows: (i) no serum vita-
min D concentration available; (ii) disorder affecting vitamin D,
PTH or calcium physiology including inflammatory bowel dis-
ease, severe liver failure, small bowel injury, giardia, chronic
diarrhoea, bariatric surgery, gastrostomy feeding, chronic renal
failure, primary hyperparathyroidism, on phenytoin; (iii) pre-
TBI disorder affecting quality of life and mood, including
psychiatric conditions (attention-deficit hyperactivity disorder,
anxiety, depression, schizophrenia, psychosis, learning difficulty),
(iv) diabetes mellitus, current alcohol excess or drug abuse; (v)
on vitamin D supplements; (vi) time since TBI >60 months to
avoid referral biases leading to worse recovery; and (vii) no
ethnicity data.
Data collection
The following data were collected: (i) patient demographics: age,
gender, ethnicity, body mass index (BMI), time since TBI, time
of year; (ii) measures of TBI severity: symptomatic, mild,
moderate–severe from Mayo classification,19 duration of post-
traumatic amnesia (PTA), neurosurgery, epilepsy; (iii) cognitive
function measured by Addenbrooke’s Cognitive Examination-
Revised (ACE-R)20; (iv) symptom questionnaire scores: Beck
Depression Inventory-II (BDI-II),21 Epworth daytime sleepiness
score,22 Pittsburgh Sleep Quality Index (PSQI)23; (v) quality-of-
life questionnaire scores: Nottingham Health Profile (NHP),24
Short Form-36 (SF-36)25; and (vi) medical and medication
history.
Outcome measures taken >1 month apart from vitamin D
measurement were excluded from the analysis due to the poten-
tial for recovery over time (>2 months for BMI given its greater
stability). BMI measurements from patients with limb amputa-
tions were excluded as an inaccurate measure of body composi-
tion. As ACE-R score in part depends on understanding,
language and fluency, scores taken from individuals with clear
English language difficulties reported in clinic were also excluded
(n = 12 total, n = 6 darker skinned).
Serum vitamin D and parathyroid hormone
Serum 25(OH)D3 and PTH concentrations were measured by
the Department of Chemical Pathology, ICHNT, using Archi-
tect chemiluminescent microparticle immunoassay (CMIA) 25
(OH)D3 assay and in vitro CMIA Architect Intact PTH assay
(Abbott Laboratories, Wiesbaden, Germany). To convert vita-
min D concentrations from nmol/L to ng/mL divide by 2496.
Vitamin D status was stratified into categories based on the
ICHNT guidelines: normal >70 nmol/l (>280 ng/ml), insuffi-
cient 40–70 nmol/l (160–280 ng/ml) and deficient <40 nmol/l
(<160 ng/ml). PTH was stratified into two categories based
on standard laboratory ranges: normal 11–68 pmol/l; high
>68 pmol/l.
Covariates
Skin colour was characterized by ethnicity, as either lighter
skinned (including White, European Caucasian, Middle Eastern,
Chinese or South East Asian) or darker skinned (Black, Indian
subcontinent, South Asian, or Mixed including these ethnicities).
Season was determined using the date of vitamin D sampling.
Winter referred to samples taken during Daylight Saving Time
© 2016 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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(DST) (1st November to 31st March), and summer to British
Summer Time (BST) (1st April to 31st October).
Statistical analysis
Data were analysed using SPSS v.22 (IBM, Armonk, NY, USA).
Each variable was tested for normality using the Kolmogorov–
Smirnov test. Data are presented as median (interquartile range)
(min–max) as they were non-normally distributed. Nonparamet-
ric Kruskal–Wallis one-way ANOVA was used to determine differ-
ences between the three vitamin D status groups for continuous
variables, and Mann–Whitney U-test for the two PTH category
groups. Chi-squared tests were performed to determine differ-
ences between groups in categorical demographic variables.
Two-way ANOVA with post hoc least significance difference
(LSD) test determined the influence of skin colour and season
between-subject variables on serum vitamin D concentrations.
One-way ANCOVA with post hoc LSD test determined differences
between vitamin D groups when controlling for covariates: age,
gender, time since TBI and severity of TBI (classified as symp-
tomatic mild or moderate–severe, or as PTA less or greater than
1 week). Log10-transformed values were used for age and time
since TBI, as they were not normally distributed.
Spearman’s bivariate correlation coefficient examined the rela-
tionship between vitamin D concentrations and outcome mea-
sures. Partial correlation coefficients were determined when
including covariates: age, gender, time since TBI and severity of
TBI, in the model.
Significance was taken as P < 005. Due to multiple compar-
isons between the subdomains of quality-of-life questionnaires,
Bonferroni correction was applied to SF-36 and NHP scores,
with significance taken as P < 0006 in SF-36 (9 subdomains)
and P < 0008 in NHP (6 subdomains).
Results
Cohort demographics
After exclusion criteria were applied, 353 patients were included
in the final analysis (Fig. 1). Only 3% of patients were excluded
All new paents seen
n = 581
No vitamin D measurement available
n = 26 (4.5%)
IBD, bariatric surgery, severe liver failure, small bowel 
injury, PEG, chronic renal failure, 1o hyperparathyroidism 
n = 14 (2.4%)
Psychiatric condion (ADHD, depression, schizophrenia, 
psychosis, learning disability)
n = 73 (12.6%)
Type 1 or Type 2 DM
n = 34 (5.9%)
On vitamin D supplementaon
n = 20 (3.4%)
Current alcohol excess or drug abuse
n = 48 (8.3%)
Time since TBI > 60 months
n = 39 (6.7%)
Included in ﬁnal analysis
n = 353
No ethnicity data available
n = 27 (4.6%)
Excluded
Lighter-skin 
n = 266
Darker-skin
n = 87
On phenytoin
n = 10 (1.7%)
Deﬁcient
46.5%
Insuﬃcient
33.7%
Replete
19.8%
35.3%39.5%25.2%
80.5%16.1%3.4%
Vitamin D status
Fig. 1 Patient inclusion and exclusion flow chart.
Data on prevalence of vitamin D status are given at
bottom of chart. Abbreviations: ADHD, attention-
deficit hyperactivity disorder; DM, diabetes
mellitus; IBD, inflammatory bowel disease; PEG,
percutaneous endoscopic gastrostomy; TBI,
traumatic brain injury.
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as they were on vitamin D supplementation. Demographic
characteristics of the cohort are shown in Table 1 and
Table S4. As typical for TBI, patients were generally young men
(median age 351 years, 748% male). 754% were of the lighter
skinned ethnic categories. The causes of TBI were as follows:
road traffic accidents (33%), falls (31%), assault (17%), sports
injuries (6%), improvised explosive device blast TBI (5%),
object falling on head (5%), other (1%) and unknown (2%).
Vitamin D status
In total, 465% of patients had vitamin D deficiency and an
additional 337% were insufficient, with only 198% being
replete (Fig. 1). The expected relationship between low vitamin
D and high PTH concentrations was seen (Table 1, Figure S1).
There was a significant difference in age, skin colour, BMI, and
season between the three vitamin D categories, but no differ-
ences were found in gender or time since TBI (Table 1).
Patients with vitamin D deficiency were significantly younger
than those who were replete (P < 005). There were a greater
proportion of darker skinned ethnicities present in the vitamin
D-deficient group compared with the other two groups
(P < 005). Patients with vitamin D insufficiency also had a
higher BMI compared with patients in the other two groups. A
significantly higher proportion of samples were taken in the
winter in patients with vitamin D deficiency.
Season and skin colour
Vitamin D concentrations were affected by both season and
skin colour (Fig. 2a). Darker skin ethnicities had significantly
lower vitamin D compared with lighter skin ethnicities (effect
size mean  SEM (95% CI) 218  28 nmol/l (163, 273),
F(1,349) = 604, P < 0001, Cohen’s d = 083). Vitamin D con-
centrations were significantly lower in the winter compared
with the summer (effect size 132  28 (77, 187),
F(1,349) = 222, P < 0001, Cohen’s d = 034). There was,
however, no interaction between skin colour and season on
vitamin D (F(1,349) = 1970, P = 016).
Comparison with general population
To gain an estimation of whether the prevalence of vitamin D
insufficiency/deficiency after TBI was greater than would be
expected in the general population, our results were compared
with a UK nationwide cohort study of White British subjects
aged 45 years (Table 2).17 The prevalence of vitamin D concen-
trations <40 and <75 nmol/l in White British and European
Caucasian patients after TBI was significantly higher than in
the general population in summer (22 vs 15%, P = 0037; 70 vs
61%, P = 0022), but not in winter.
Markers of TBI severity
There was no significant difference in markers of TBI severity:
PTA duration, or prevalence of moderate–severe TBI, cran- T
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iotomy or epilepsy between the vitamin D groups (Table 3).
This remained nonsignificant even after correction for age, skin
colour and season.
Vitamin D status and outcome measures
Patients with Vitamin D deficiency had significantly lower ACE-
R scores compared to patients with vitamin D insufficiency
(P = 0003) (Table 4). This significance remained after correc-
tion for age, gender, time since TBI and TBI severity, using
either PTA >1 week (effect size 52  16 (95% CI 21–83),
P = 0001, Cohen’s d = 056) (Fig. 2b), or prevalence of moder-
ate–severe TBI (effect size 49  15 (19–79), P = 0002,
Cohen’s d = 054), as markers of severity. After correction for
these factors, patients with vitamin D deficiency also had signifi-
cantly lower ACE-R scores than patients who were replete (effect
size 45  21 (03–86), P = 0034, Cohen’s d = 048).
In stepwise linear regression, vitamin D status (F-to-
enter = 670, r = +018, P = 0010), but not skin colour
(P = 057) or season (F = 028), also correlated with ACE-R
score. Additionally, this significance also remained when the
analysis was restricted to just lighter skin ethnic individuals, in
order to exclude many of those who may be less proficient in
English as a second language (F(2,124) = 45, P = 0013; effect
size vs insufficient, 54  18 (18–91), P = 0004, Cohen’s
d = 059; effect size vs replete, 46  23 (001–911), P = 0050,
Cohen’s d = 049).
In the uncorrected model, vitamin D status was not signifi-
cantly associated with BDI-II score (Table 4). However, patients
with vitamin D deficiency had significantly higher BDI-II scores
compared to those with insufficiency when corrected for age,
gender, time since TBI and TBI severity, using both PTA
>1 week (effect size 49  16 (17–81), P = 0003, Cohen’s
d = 042) (Fig. 2c) or prevalence of moderate–severe TBI (effect
Fig. 2 Relationship between Vitamin D status and
skin colour, season, cognition and depressive
symptoms. (a) Influence of skin colour and season
on serum vitamin D concentrations; (b, c)
influence of vitamin D status on (b) cognition
assessed by ACE-R scores and (c) depressive
symptoms assessed by BDI-II; and (d) correlation
between serum vitamin D concentrations and ACE-
R score. Statistical results from (a) two-way ANOVA
including skin colour and ethnicity as between-
subject factors, indicating a significant effect of skin
colour and season but no interaction effect
(n = 353); (b, c) one-way ANCOVA including vitamin
D status group as between-subject factor, correcting
for age, gender, time since TBI and PTA duration
>1 week, *P < 005, **P < 001 (b: n = 27 replete,
n = 66 insufficient, n = 77 deficient; c: n = 53
replete, n = 95 insufficient, n = 123 deficient); (d)
rs indicates Spearman’s correlation coefficient,
n = 175. Abbreviations: ACE-R, Addenbrooke’s
Cognitive Examination-Revised, BDI-II, Beck
Depression Inventory-II; PTA, post-traumatic
amnesia; TBI, traumatic brain injury. To convert
vitamin D concentrations from nmol/l to ng/ml
divide by 2496.
Table 2. Prevalence of vitamin D deficiency in white Caucasians
compared to a UK survey
n
Vitamin D
<25 nmol/l <40 nmol/l <75 nmol/l
DST/Winter
Current Audit 119 21 (176%) 63 (529%) 108 (908%)
UK Survey 2850 441 (155%) 1328 (466%) 2482 (871%)
Chi Statistic 041 185 276
P Value 052 017 0097
BST/Summer
Current Audit 142 5 (35%) 31 (218%) 100 (704%)
UK Survey 4587 147 (32%) 706 (154%) 2793 (609%)
Chi Statistic 0044 434 527
P Value 083 0037 0022
Prevalence of vitamin D status in current audit (for white Caucasians
only) was compared using chi-squared test to UK survey data for white
Caucasians reported by Hypponen E and Power C. Hypovitaminosis D
in British adults at age 45 year: nationwide cohort study of dietary and
lifestyle predictors. Am J Clin Nutr 2007 85:860–868.
Abbreviations: BST, British Summer Time; DST, Daylight Saving Time;
UK, United Kingdom.
To convert vitamin D concentrations from nmol/l to ng/ml divide by
2496. P values in bold text indicate statistically significant results.
© 2016 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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size 43  15 (13–74), P = 0005, Cohen’s d = 038). Season
had no significant effect on BDI-II score (winter vs. sum-
mer effect size 15  13 (42, 11), P = 025, Cohen’s
d = 014).
Vitamin D status did not influence Epworth daytime sleepi-
ness or PSQI scores, or any components of the SF-36 and NHP
questionnaires, even after correction for age, gender, time since
TBI and TBI severity (Table 4).
Vitamin D concentrations and outcome measures
Vitamin D concentrations were significantly correlated with per-
formance on the ACE-R (rs = +018, P = 0017) (Table S5). This
remained significant when corrected for age, gender, time since
TBI and TBI severity, using both PTA >1 week (rs = +018,
P = 0021) (Fig. 2d) and prevalence of moderate–severe TBI
(rs = +018, P = 0017).
There was, however, no significant correlation between vita-
min D concentrations and symptom scores on BDI-II, Epworth
or PSQI, or quality-of-life measures from SF-36 or NHP
(Table S5).
PTH status and outcome measures
There was no significant association between PTH status,
defined as high or normal, and cognition, symptoms scores or
quality-of-life measures in either the whole cohort (P = 021–
094), or those that were vitamin D deficient (P = 014–099),
insufficient (P = 007–096) or nonreplete (P = 010–093).
Discussion
This study has found that vitamin D deficiency is common in
patients after TBI with 465% of patients being vitamin D defi-
cient, and a further 337% being insufficient, with overall 802%
having low concentrations. This prevalence of vitamin D insuffi-
ciency/deficiency in summer in White and European Caucasian
individuals after TBI was greater than expected in the general
population (using a UK nationwide cohort study of the White
British population aged 45 years).17 This was despite the fact
that the UK survey included areas of greater latitude, such as
Scotland, with higher prevalence of vitamin D deficiency, which
would be expected to attenuate this difference.
In agreement with other studies in non-TBI patients,7,8 this
study found that low vitamin D status was negatively correlated
with cognition as assessed by the ACE-R, even after adjustment
for factors that may influence performance, including age, gen-
der, time since TBI and TBI severity.26–28
When corrected for age, gender, and other factors that may
influence BDI-II score,29,30 vitamin D deficiency was also associ-
ated with more severe depressive symptoms. This is in agree-
ment with previous meta-analyses in non-TBI patients, which
show an association between vitamin D concentrations and
depression (Table S2).5,6
These associations with cognition and depressive symptoms
may result from a role for vitamin D in brain function.31 Many
brain cell types and regions can synthesize the active form of
vitamin D, 1,25(OH)D3, including the hypothalamus and sub-
stantia nigra,11 areas implicated in the pathophysiology of
depression. Vitamin D modulates the production of neuropro-
tective factors and neurotransmitters (including growth factors
and choline acetyltransferase), neuronal apoptosis, neuroinflam-
mation, oxidative stress, excitotoxicity, and myelin and axon
repair.8,32
In rat models of TBI, vitamin D deficiency leads to greater
open-field behavioural deficits and attenuates the beneficial
effects of progesterone administration.4 This is reversed by co-
administration of vitamin D,4 which also improves spatial mem-
ory processing.12 Changes in neuroinflammation may be a link-
ing mechanism as vitamin D deficiency is associated with
elevated brain inflammatory proteins with, and even without,
TBI.4 Vitamin D administration reduces neuronal loss and mod-
ifies the proliferation of reactive astrocytes.12,14
There was no association found between vitamin D status and
sleep, or any quality-of-life domains on the NHP and SF-36.
This is contradictory to previous research in premenopausal
women, and women with chronic pain (unlike current study
where 748% were male), where vitamin D deficiency is associ-
ated with worse SF-36 and NHP quality-of-life scores, particu-
larly in vitality, physical and mental component subscores.33,34
Table 3. Relationship between vitamin D status and markers of TBI severity
Variable Units n All subjects n
Vitamin D
replete n
Vitamin D
insufficient n
Vitamin D
deficient
Uncorrected
Corrected for: age,
skin color season
v statistic P F statistic P*
Moderate-Severe TBI n (%) 353 263 (745%) 70 51 (729%) 119 93 (782%) 164 119 (726%) 126 053 099 F(2,347) 059
PTA > 1 day n (%) 328 154 (433%) 66 33 (471%) 109 55 (462%) 153 66 (402%) 168 043 106 F(2,321) 035
PTA > 1 week n (%) 328 67 (190%) 66 13 (186%) 109 27 (227%) 153 27 (165%) 201 037 113 F(2,321) 033
Craniotomy n (%) 353 2 (06%) 70 1 (14%) 119 1 (08%) 164 0 (0%) 202 037 199 F(2,347) 014
Epilepsy n (%) 353 47 (133%) 70 10 (143%) 119 16 (134%) 164 21 (128%) 010 095 041 F(2,347) 067
Values stated as n (%).
Statistical results from Chi-squared test, except for *one way ANCOVA when controlling for covariates.
Abbreviations: PTA, post-traumatic amnesia; TBI, traumatic brain injury.
© 2016 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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However, there are many factors that may affect quality of life,
in addition to mood and cognitive function.
It is hypothesized that TBI may increase the prevalence of
vitamin D insufficiency/deficiency as a result of hospitalization,
impaired social functioning and absence from work, reducing
sun exposure. However, in this audit, no markers of TBI severity
influenced vitamin D status. This may be related to type II
errors as some of the measures, such as need for neurosurgery
and presence of epilepsy, were uncommon. In addition, TBI
severity determined by duration of PTA and presence of
intracranial pathology may not be relevant as a risk factor for
sun exposure, given that the median time after TBI was
44 months.
Furthermore, vitamin D plays a major role in bone
homoeostasis and can reduce risk of fracture and rate of bone
loss in those over 50 years old.35 Thus, irrespective of the rela-
tionship between vitamin D status and cognition/depression,
screening and treating patients after TBI could be justified to
improve healing of any associated fractures, and bone health,
especially as they become less active. This is a neglected treat-
ment avenue as only 3% of our cohort were taking vitamin D
supplements when vitamin D status was initially assessed at their
first TBI clinic appointment.
There are several limitations with this study. Most impor-
tantly, this is an association study, and so the direction of
causality seen in the results is unknown. Although vitamin D
deficiency may be contributing to impaired cognitive function
or higher depressive symptoms, this cannot be proven from this
study. TBI itself can cause these symptoms, leading to individu-
als spending more time indoors and thus becoming more vita-
min D deficient. However, meta-analyses of intervention studies
in non-TBI patients have shown that vitamin D supplementation
improves depressive symptoms, suggesting causation (Table S3).
There is a currently a lack of intervention studies looking at the
effects of vitamin supplementation and cognition, and further
work is needed to clarify the direction of this association. Fur-
thermore, this audit did not include a control group to allow
comparison of prevalence data in individuals utilizing the same
vitamin D assay. Finding a suitable control group from other
studies is difficult due to differences in demographics and vari-
ability in the assay used.
There are also limitations regarding categorizing skin colour
based on ethnicities of patients. Although Middle Eastern and
eastern European individuals were considered to be lighter
skinned, they may have greater levels of melanin than White
Caucasians. Similarly, the categorization of season into DST and
BST does not allow separation of all four seasons. However,
appropriate relationships were seen between skin colour and sea-
son with vitamin D in our study, indicating that our approach
gave biologically relevant results.17,18 Reduced strength and
duration of sunlight during winter and diversity of ethnicity in
the UK will increase the clinical risk of vitamin D deficiency in
our TBI clinic population.
Due to the potential limitations with the ACE-R in those less
proficient in English, a further development would be to use
only measures of cognitive function that do not depend on lan-
guage, such as memory, visuospatial and attention/orientation
subcomponents. Alternatively, neuropsychological tests more
specific to consequences after TBI could be used, for example
focusing on planning, concentration and switching.
In conclusion, vitamin D deficiency is common in patients
after TBI and is associated with worse cognitive function and
more severe depressive symptoms. There is a potential for vita-
min D to be a modifiable risk factor to improve recovery after
TBI. Further work is needed to examine the longitudinal effects
of vitamin D status and supplementation on neurocognitive and
psychological function and neuroimaging biomarkers to deter-
mine whether assessment and treatment of vitamin D deficiency
should become part of clinical guidelines in the management of
TBI.
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